Back to resultsRDS MultiSense® SpO2 Validation Study
Primary Purpose
Hypoxia
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Pulse Oximeter, Respiratory Rate, Heart Rate and Arterial line
Sponsored by
About this trial
This is an interventional other trial for Hypoxia focused on measuring Hypoxia, Pulse Oximetry, SpO2, Remote Monitoring, Connected device, Real-time monitoring
Eligibility Criteria
Inclusion Criteria:
- 10-15 Adults with a minimum of 3 males and a minimum of 3 females, with the balance made up of either
- Participant must have the ability to understand and provide written informed consent
- Participant is 18 to 50 years of age
- Participant must be willing and able to comply with study procedures and duration
- Participant is a non-smoker or who has not smoked within 2 days prior to the study
Exclusion Criteria:
- Participant is considered as being morbidly obese (defined as BMI >39.5)
- Compromised circulation, injury, or physical malformation of fingers, wrist, hands, ears or forehead/skull or other sensor sites, tattoo, extensive moles, or freckles in the optical path which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow participants to participate if the condition is noted and would not affect the particular sites utilized.)
- Female participants that are actively trying to get pregnant or are pregnant (confirmed by positive urine pregnancy test unless the participant is known to be not of child-bearing potential).
- Smoker participants who have refrained will be screened for Carboxyhemoglobin (COHb) levels >3% as assessed with a reference devie (Masimo Radical 7)
- Participants with known respiratory conditions (self-reported)
- Participants with known heart or cardiovascular conditions (self-reported, except for blood pressure and ECG review)
- Self-reported health conditions as identified in the Health Assessment Form (self-reported)
- Participants with known clotting disorders (self-reported)
- Participants with severe contact allergies to standard adhesives, silicon, latex or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors (self-reported)
- Participants with severe allergies to iodine (only applicable if iodine is used)
- Participants with severe allergies to lidocaine (or similar pharmacological agents, e.g. Novocaine)
- Failure of the Perfusion Index Ulnar/Ulnar+Radial Ratio test (Ratio < 0.4)
- Unwillingness or inability to remove colored nail polish from test digits.
- Unwillingness to have chest or other test sites shaved
- Other known health condition, should be considered upon disclosure in health assessment form
Sites / Locations
- Clinimark LLC
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Controled Hypoxia - Healthy Volunteers
Arm Description
Outcomes
Primary Outcome Measures
Validation of SpO2 accuracy performance of RDS MultiSense® Pulse Oximeter by comparison to CO-Oximeter
The Accuracy Root Mean Square (Arms) value will be used as a metric. Reference CO-Oximetry will be used as the basis for comparison for the investigational device SpO2 readings.
Secondary Outcome Measures
Evaluation of heart rate accuracy performance of RDS MultiSense® by comparison to ECG-derived heart rate
The reference for comparison of the investigational device heart rate will be heart rate values collected from an ECG monitor.Heart rate accuracy will be assessed by review of the readings less than ±5 Beats Per Minute or ±10% from the Reference heart rate values.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05359328
Brief Title
RDS MultiSense® SpO2 Validation Study
Official Title
RDS MultiSense® SpO2 Validation Study
Study Type
Interventional
2. Study Status
Record Verification Date
July 2022
Overall Recruitment Status
Completed
Study Start Date
April 26, 2022 (Actual)
Primary Completion Date
April 29, 2022 (Actual)
Study Completion Date
April 29, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Rhythm Diagnostic Systems
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this clinical study is to validate the oxygen saturation (SpO2) accuracy of the RDS MultiSense® Pulse Oximetry during non-motion conditions over the range of 70-100% arterial oxygen saturation (SaO2) as compared to arterial blood samples assessed by measuring carbon monoxide (CO) bound to hemoglobin by CO-Oximetry. Additionally, data will be collected for heart rate accuracy as compared to reference ECG. The end goal is to provide supporting documentation for the SpO2 and heart rate accuracy validation for RDS MultiSense® Pulse Oximetry.
A minimum of 10 healthy adult male and female participants, ranging in age and pigmentation from light to dark, will be enrolled in the study to meet the study design requirements defined by International Organization for Standardization ISO 80601-2-61:2017: corrected version 2018-02 and by the FDA's Guidance for Pulse Oximeters (March 4, 2013). The participants will have an arterial catheter placed in the radial artery to allow for simultaneous blood samples during stable plateaus of induced hypoxic levels.
The investigational device will be placed on the placed on the thorax of the participants (patch on the upper back and external electrode on the right pectoral) per the instructions for use. Simultaneous data collection will be set up for the system under test and control oximeter.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypoxia
Keywords
Hypoxia, Pulse Oximetry, SpO2, Remote Monitoring, Connected device, Real-time monitoring
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Controled Hypoxia - Healthy Volunteers
Arm Type
Other
Intervention Type
Device
Intervention Name(s)
Pulse Oximeter, Respiratory Rate, Heart Rate and Arterial line
Intervention Description
Measurement of physiological parameters
Primary Outcome Measure Information:
Title
Validation of SpO2 accuracy performance of RDS MultiSense® Pulse Oximeter by comparison to CO-Oximeter
Description
The Accuracy Root Mean Square (Arms) value will be used as a metric. Reference CO-Oximetry will be used as the basis for comparison for the investigational device SpO2 readings.
Time Frame
From beginning to end of controled hypoxia, up to 2 hours
Secondary Outcome Measure Information:
Title
Evaluation of heart rate accuracy performance of RDS MultiSense® by comparison to ECG-derived heart rate
Description
The reference for comparison of the investigational device heart rate will be heart rate values collected from an ECG monitor.Heart rate accuracy will be assessed by review of the readings less than ±5 Beats Per Minute or ±10% from the Reference heart rate values.
Time Frame
From beginning to end of monitoring, up to 2 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
10-15 Adults with a minimum of 3 males and a minimum of 3 females, with the balance made up of either
Participant must have the ability to understand and provide written informed consent
Participant is 18 to 50 years of age
Participant must be willing and able to comply with study procedures and duration
Participant is a non-smoker or who has not smoked within 2 days prior to the study
Exclusion Criteria:
Participant is considered as being morbidly obese (defined as BMI >39.5)
Compromised circulation, injury, or physical malformation of fingers, wrist, hands, ears or forehead/skull or other sensor sites, tattoo, extensive moles, or freckles in the optical path which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow participants to participate if the condition is noted and would not affect the particular sites utilized.)
Female participants that are actively trying to get pregnant or are pregnant (confirmed by positive urine pregnancy test unless the participant is known to be not of child-bearing potential).
Smoker participants who have refrained will be screened for Carboxyhemoglobin (COHb) levels >3% as assessed with a reference devie (Masimo Radical 7)
Participants with known respiratory conditions (self-reported)
Participants with known heart or cardiovascular conditions (self-reported, except for blood pressure and ECG review)
Self-reported health conditions as identified in the Health Assessment Form (self-reported)
Participants with known clotting disorders (self-reported)
Participants with severe contact allergies to standard adhesives, silicon, latex or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors (self-reported)
Participants with severe allergies to iodine (only applicable if iodine is used)
Participants with severe allergies to lidocaine (or similar pharmacological agents, e.g. Novocaine)
Failure of the Perfusion Index Ulnar/Ulnar+Radial Ratio test (Ratio < 0.4)
Unwillingness or inability to remove colored nail polish from test digits.
Unwillingness to have chest or other test sites shaved
Other known health condition, should be considered upon disclosure in health assessment form
Facility Information:
Facility Name
Clinimark LLC
City
Louisville
State/Province
Colorado
ZIP/Postal Code
80027
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
RDS MultiSense® SpO2 Validation Study
We'll reach out to this number within 24 hrs